We stay close to our portfolio companies. Here's how they're doing.

Featured
MMI Earns Gold Edison Award for Symani(R), Recognized for Expanding Access to Life-Changing Surgical Treatment Options
MMI Earns Gold Edison Award for Symani(R), Recognized for Expanding Access to Life-Changing Surgical Treatment Options
Exciva appoints distinguished biopharma leaderMark Altmeyer as chairman of the board
Exciva appoints distinguished biopharma leaderMark Altmeyer as chairman of the board
MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study
MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round
MMI Introduces World’s First Microsurgical Suture for Robotics
MMI Introduces World’s First Microsurgical Suture for Robotics
XyloCor Appoints John Tucker as President and Chief Executive Officer
XyloCor Appoints John Tucker as President and Chief Executive Officer
Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System
Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System
Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing
Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing
Exciva raises €51 million ($59m) in Series B funding round
Exciva raises €51 million ($59m) in Series B funding round
Haemonetics Acquires Vivasure Medical Limited
Haemonetics Acquires Vivasure Medical Limited
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8
MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani
MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani
Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer
MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery
MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery
Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists
Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
Priothera Secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Priothera Secures EUR1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System
Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Neuromod Closes €10m Financing to Accelerate Commercialisation
Neuromod Closes €10m Financing to Accelerate Commercialisation
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
View All Posts by Company